Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / FUSMobile Inc.

Clinicaltrial registered9 Nov 2026

FUSMobile Inc.

9 Nov 2026: Trial registered · Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
9 Nov 2026
Title
Study Designed to Assess the Efficacy and Safety of the Neurolyser XR After Marketing Approval
Conditions
Lumbar Zygapophyseal Pain, Low Back Pain, Facet Joint Pain; Low Back Pain
Study Type
Observational
Status
Not Yet Recruiting
Countries
Spain
Country
Spain
Reference
NCT07926581
Location
Spain
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at FUSMobile Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for FUSMobile Inc. in our registers.

More from Spain

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.